CARDENE I.V. adverse reactions: Difference between revisions
No edit summary |
|||
| Line 37: | Line 37: | ||
Urogenital: urinary frequency | Urogenital: urinary frequency | ||
Sinus node dysfunction and myocardial infarction, which may be due to disease progression, have been seen in patients on chronic therapy with orally administered nicardipine.'' | Sinus node dysfunction and myocardial infarction, which may be due to disease progression, have been seen in patients on chronic therapy with orally administered nicardipine.''<ref> {{cite web | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8ef8420-01d2-11de-a455-0002a5d5c51b | title = CARDENE I.V. (nicardipine hydrochloride) injection, solution [EKR Therapeutics, Inc.] |accessdate = }}</ref> | ||
==References== | |||
{{Reflist|2}} | {{Reflist|2}} | ||
{{FDA}} | |||
[[Category:Cardiovascular Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 16:31, 20 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: :Abdurahman Khalil, M.D. [2]
For patient information about Nicardipine, click here.
ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
Two hundred forty-four patients participated in two multicenter, double-blind, placebo-controlled trials of Cardene I.V. Adverse experiences were generally not serious and most were expected consequences of vasodilation. Adverse experiences occasionally required dosage adjustment. Therapy was discontinued in approximately 12% of patients, mainly due to hypotension, headache, and tachycardia.
The table below shows percentage of patients with adverse events where the rate is >3% more common on Cardene I.V. than placebo.
Other adverse events have been reported in clinical trials or in the literature in association with the use of intravenously administered nicardipine:
Body as a Whole: fever, neck pain
Cardiovascular: angina pectoris, atrioventricular block, ST segment depression, inverted T wave, deep-vein thrombophlebitis
Digestive: dyspepsia
Hemic and Lymphatic:thrombocytopenia
Metabolic and Nutritional: hypophosphatemia, peripheral edema
Nervous: confusion, hypertonia
Respiratory: respiratory disorder
Special Senses: conjunctivitis, ear disorder, tinnitus
Urogenital: urinary frequency
Sinus node dysfunction and myocardial infarction, which may be due to disease progression, have been seen in patients on chronic therapy with orally administered nicardipine.[1]
References
Adapted from the FDA Package Insert.